BioMarin Pharmaceutical Inc. has reported strong financial results for the second quarter ended June 30, 2025. The company achieved total revenues of $825 million, marking a 16% year-over-year increase, or 17% at constant currency. The GAAP diluted earnings per share $(EPS)$ rose significantly by 124% compared to the previous year, reaching $1.23. Additionally, the non-GAAP diluted EPS increased by 50% year-over-year to $1.44. BioMarin has also updated its full-year 2025 guidance, raising expectations for total revenues, non-GAAP operating margin, and non-GAAP diluted EPS. The improved guidance reflects robust growth in patient demand across its portfolio and the company's strategic focus on enhancing profitability and cash flow to fuel further innovation and growth. In terms of business developments, BioMarin completed the acquisition of Inozyme in July 2025 and anticipates pivotal data from their lead indication in the first half of 2026. The company is also advancing its pipeline with BMN 333, which exceeded targeted exposures in a healthy volunteer study. A pivotal Phase 2/3 study with BMN 333 in pediatric achondroplasia is planned to commence in the first half of 2026.